Feasibility of Converting Inhaled Epoprostenol Product From Flolan to Veletri in Critically Ill Patients

Am J Ther. 2020 Oct 1;28(6):e781-e785. doi: 10.1097/MJT.0000000000001142.
No abstract available

Publication types

  • Letter

MeSH terms

  • Administration, Inhalation
  • Antihypertensive Agents / adverse effects
  • Critical Illness
  • Epoprostenol*
  • Feasibility Studies
  • Humans
  • Hypertension, Pulmonary* / drug therapy
  • Vasodilator Agents / therapeutic use

Substances

  • Antihypertensive Agents
  • Vasodilator Agents
  • Epoprostenol